# Dan T. Vogl

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/dan-t-vogl/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,317 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 50 |
| i10-index | 126 |
| Last Known Institution | University of Pennsylvania |
| OpenAlex ID | https://openalex.org/A5041561013 |
| ORCID iD | https://orcid.org/0000-0002-2935-2566 |
| Works | 363 |

## Researcher papers

- [NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma](https://scholariq.org/papers/ny-eso-1-specific-tcr-engineered-t-cells-mediate-sustained-antigen-specific/)
- [Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients](https://scholariq.org/papers/lectin-type-oxidized-ldl-receptor-1-distinguishes-population-of-human/)
- [B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma](https://scholariq.org/papers/b-cell-maturation-antigen-specific-car-t-cells-are-clinically-active-in-multiple/)
- [Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma](https://scholariq.org/papers/oral-selinexor-dexamethasone-for-triple-class-refractory-multiple-myeloma/)
- [Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma](https://scholariq.org/papers/chimeric-antigen-receptor-t-cells-against-cd19-for-multiple-myeloma/)
- [Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial](https://scholariq.org/papers/autologous-transplantation-consolidation-and-maintenance-therapy-in-multiple/)
- [Symptom Prevalence, Characteristics, and Distress in AIDS Outpatients](https://scholariq.org/papers/symptom-prevalence-characteristics-and-distress-in-aids-outpatients/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

## Researcher university

- [University of Pennsylvania](https://scholariq.org/institutions/university-of-pennsylvania/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.